Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…